Overexpression of XXXX predicts @entity14 risk in @entity1 with @entity29 and mucosa changes indefinite for @entity1141 .

@entity1 @entity5 @entity29 @entity876 @entity5822 @entity14 @entity1141
BACKGROUND AND AIMS: We previously demonstrated a significant @entity14 risk in @entity29 ( @entity29 ) @entity1 with mucosal changes indefinite for @entity1141 (IND) and the potential diagnostic utility of @entity876 and @entity5822 immunohistochemistry in @entity29 -associated @entity5 . The primary aim of this exploratory study was to determine the predictive value of the two markers for @entity5 risk in the @entity29 -IND population. METHODS: We identified 44 eligible cases with @entity29 and IND in colon biopsy from our pathology database. We semi-quantified the expression of @entity876 and @entity5822 in the colon biopsies by immunohistochemistry and correlated their expression, demographic information, and clinical features with @entity14 outcome. RESULTS: The mean age of the cohort was 46.6        15.1 years, with 25 (56.8%) being male. The median follow-up was 101 months (range: 6-247) after IND diagnosis. Among these 44 @entity1 , 11 (25%) progressed to @entity5 (low-grade @entity1141   =   6; high-grade @entity1141   =   2; @entity5 3) at a median follow-up of 66 months (range: 19-145). Univariate analysis demonstrated that age and @entity876 overexpression were associated with progression to @entity5 . CONCLUSIONS: Twenty-five percent of @entity1 with @entity29 and IND developed @entity14 or @entity5 . Overexpression of @entity876 and age are associated with @entity5 progression.
